Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
By R. Jakesz, W. Jonat, M. Gnant, M. Mittlboeck, R. Greil, C. Tausch, J. Hilfrich, W. Kwasny, C. Menzel, H. Samonigg and 4 more. The Lancet, 2005
903 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics
View Paper: https://www.semanticscholar.org/paper/d17ced0878691ec9c0669c07a87a7dc76b8f9261
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- W. Wood
- M. Filipits
- M. Rudas
- R. Jakesz
- H. Senn
- P. Dubsky
- Panel Members
- M. Gnant
Citations in the corpus
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, background): “Clearly the availability of third generation aromatase inhibitors (AIs) [24, 84–88] has added substantially to the available treatment choice after a quarter century of successful use of tamoxifen.”
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011, background): “Inclusion criteria and themain clinical results of these trials were reported previously (8, 9).”